The cancer quandary: improving outcomes as costs explode:

It long has been the dreaded C diagnosis: Cancer. For many Americans, the memory persists of a dreadful, deadly disease. But medical science has changed that, and, for millions, cancer has become a chronic not a killer condition. Many of us struggle with and survive it.

Still, even in the careful coverage about advances in combatting cancer, there it arises: the dollar sign. Recent reports about impressive results from immunotherapies, though brimming with optimism about getting the body’s own systems to fight back, also include the startling figure about the cost of just one year’s dosages for one patient receiving a mass-produced anti-cancer drug: $150,000...